Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 2:14:1402970.
doi: 10.3389/fonc.2024.1402970. eCollection 2024.

The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report

Yueru Ji  1 , Zhuo Wan  1 , Jian Yang  1 , Miaowang Hao  1 , Li Liu  1 , Weiwei Qin  1
Affiliations
Case Reports

The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report

Yueru Ji et al. Front Oncol. .

Abstract

FLT3-ITD is a type of poor prognostic factors in acute myeloid leukemia (AML) disease. Gilteritinib, the second-generation FLT3 tyrosine kinase inhibitor, improved the overall survival of patients with relapsed/refractory FLT3-mutated AML in the ADMIRAL phase III trial. However, few data are available on the efficacy and safety of gilteritinib-based therapy for FLT3-mutated AML with central nervous system (CNS) involvement. We performed gilteritinib to treat a patient with CNS relapsed AML after allogeneic hematopoietic stem cell transplantation. The positive antileukemic effect of gilteritinib may bring new hope for the treatment of FLT3-mutated AML with CNS relapse.

Keywords: AML; CNS relapse; FLT3-ITD; gilteritinib; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Previous chemotherapy regimens and treatment response.
See this image and copyright information in PMC

References

    1. Haage TR, Schraven B, Mougiakakos D, Fischer T. How ITD insertion sites orchestrate the biology and disease of FLT3-ITD-mutated acute myeloid leukemia. Cancers (Basel). (2023) 15:2991. doi: 10.3390/cancers15112991 - DOI - PMC - PubMed
    1. Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, et al. . Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. (2022) 140:1845–57. doi: 10.1182/blood.2021014586 - DOI - PMC - PubMed
    1. Song MK, Park BB, Uhm JE. Clinical efficacies of FLT3 inhibitors in patients with acute myeloid leukemia. Int J Mol Sci. (2022) 23:12708. doi: 10.3390/ijms232012708 - DOI - PMC - PubMed
    1. Sastow D, Van Hyfte G, Feld J, Kremyanskaya M, Mascarenhas J, Tremblay D. Exclusion of acute myeloid leukemia patients with central nervous system involvement from clinical trials: An analysis of the national institutes of health clinical trials registry from 2012-2022. Acta Haematol. (2024) 147:292–9. doi: 10.1159/000533819 - DOI - PubMed
    1. Sastow D, Tatarian J, Riazat-Kesh Y, Farina K, Becker M, Feld J, et al. . Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement. Leuk Lymphoma. (2023) 64:2002–7. doi: 10.1080/10428194.2023.2248331 - DOI - PubMed

Publication types

LinkOut - more resources